However, previous clinical trials that utilized targeted therapies in biliary tract cancers have not shown clinically significant improvements in overall response rates so far (eg, 31‐33% for GEMOX or gemcitabine/irinotecan with panitumumab targeting EGFR among KRAS wild‐type biliary tract cancers; and 15% for an FGFR inhibitor among FGFR‐altered cholangiocarcinoma).11, 12, 13. The gene discussed is KRAS; the disease is biliary tract neoplasm.